Clinical trial · Interventional
Axillary Reverse Mapping Using Methylene Blue Subcutaneous Injection Can Identify Arm Lymph Nodes and Vessels, Measuring Arm Size for Lymphedema, Histopathological Examination of Arm Lymph Nodes Included With Axillary Lymph Node Dissection
Evaluation of Axillary Reverse Mapping (ARM) in Clinically Axillary Node Negative Breast Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
study patients; axillary node negative breast cancer female, 74 patients randomly allocated in two groups each 37 patients , group I , where axillary reverse mapping(ARM) +ve nodes were preserved and axillary lymph node dissection completed.and group II where axillary reverse mapping +ve nodes were taken with axillary lymph node dissection(ALND) primary outcome is histopathological examination of a ARM +ve lymph nodes and volume measurements of the ipsilateral arm for development of lymphedema at 6 ,12 , and 24 months
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Arm Lymphedema | — | UNRESOLVED | — |
| Early Breast Cancer | — | UNRESOLVED | — |
| Lymphatic Spread of Breast Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AXILLARY REVERSE MAPPING | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- ARM preservation ALND
- description
- ARM +ve LN PRESERVED , ALND COMPLETED LATER ON
- interventionNames
- Procedure: AXILLARY REVERSE MAPPING
- type
- ACTIVE_COMPARATOR
- label
- conventional ALND
- description
- ARM +VE NODES MARKED AND TAKEN WITH ALND
- interventionNames
- Procedure: AXILLARY REVERSE MAPPING
Primary outcomes (2)
- measure
- histopathologic examination of ARM +ve LN
- timeFrame
- IMMEDIATE POSTOPERATIVE
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * clinically free breast cancer * sentinle LN positive Exclusion Criteria: * patients on chemotherapy for breast cancer * recurrent cases after conservative breast surgery * bilateral disease and pregnant cases
References
Publications (0)
Data not yet available